Skip to main content

Type 2 diabetes

medwireNews top story

Women with diabetes need system-wide change to improve pregnancy outcomes

Data from the first 5 years of the UK’s National Pregnancy in Diabetes audit reveal differing effects of type 1 and type 2 diabetes on pregnancy outcomes, with no sign of improvements over time.

medwireNews top story

Glycemic benefits of metabolic surgery endure for at least 10 years

Metabolic surgery can result in type 2 diabetes remission lasting for at least 10 years, and people who relapse still achieve markedly improved glycemic control, shows follow-up from a randomized trial published in The Lancet.

medwireNews top story

AWARD 11 supports higher dulaglutide doses

Dulaglutide doses of 3.0 and 4.5 mg are significantly more efficacious than the standard doses, with similar safety profiles, report the AWARD 11 investigators.

medwireNews top story

DAPA-CKD: Dapagliflozin renoprotective regardless of underlying CKD etiology

A prespecified analysis of data from the DAPA-CKD trial suggests that add-on treatment with dapagliflozin slows decline in renal function among patients with chronic kidney disease irrespective of the underlying etiology.

medwireNews top story

Support for bariatric surgery in people with insulin-dependent type 2 diabetes

Treatment with bariatric surgery is associated with clinical and cost-saving benefits among obese people with type 2 diabetes requiring insulin, researchers report.

medwireNews top story

Metformin might protect women with type 2 diabetes against COVID-19 mortality

An observational study suggests that prior metformin use may offer a protective effect against COVID-19 mortality in people with type 2 diabetes, but only for women.

medwireNews top story

​​​​​​​Sotagliflozin SCORED cardiovascular risk reduction in people with type 2 diabetes, CKD

Add-on treatment with the SGLT1 and 2 inhibitor sotagliflozin may reduce cardiovascular risk among patients with type 2 diabetes and chronic kidney disease, suggest findings from the SCORED trial published in The New England Journal of Medicine.

medwireNews top story

SOLOIST-WHF: Sotagliflozin beneficial when started shortly after acute heart failure episode

Starting sotagliflozin in people with type 2 diabetes during or shortly after hospitalization for heart failure significantly reduces their risk for further cardiovascular events over the following months, show the results of the SOLOIST-WHF trial.

medwireNews top story

Rural inhabitants may miss out on newest diabetes medications

Geographic remoteness is strongly associated with a reduced likelihood of being prescribed the most recent classes of glucose-lowering medications, find Australian researchers.

medwireNews top story

FIDELIO-DKD: Finerenone offers new treatment option for diabetic CKD

The selective mineralocorticoid receptor antagonist finerenone significantly reduces the risk for progression of chronic kidney disease and for cardiovascular events in people with type 2 diabetes, show the FIDELIO-DKD findings.

21-09-2022 | EASD 2022 | Conference coverage | News

C-peptide may be better than CRP for predicting cardiovascular risk in type 2 diabetes

Among people with early type 2 diabetes, levels of C-peptide are more strongly associated with the risk for future cardiovascular events than levels of C-reactive protein, research suggests.

21-09-2022 | EASD 2022 | Conference coverage | News

Skin reactions rarely lead to diabetes device discontinuation

Skin reactions to glucose monitors and insulin pumps occur in more than a quarter of users but only occasionally result in device discontinuation, research shows.

20-09-2022 | EASD 2022 | Conference coverage | News

Freestyle Libre cuts acute complication risk in insulin-treated type 2 diabetes

People taking basal insulin to treat type 2 diabetes experience a significant reduction in the risk for acute complications, which is sustained for at least 2 years after initiating use of the Freestyle Libre, say French researchers.

Illustration showing CGM communicating with Insulin Pump

20-09-2022 | EASD 2022 | Conference coverage | News

​​​​​​​Fully closed-loop control boosts TIR in insulin-treated type 2 diabetes

A fully closed-loop insulin delivery system markedly increases time in range for people with insulin-treated type 2 diabetes, shows a small randomized crossover trial.

13-09-2022 | Risk factors | News

Subjective energy levels predict cardiovascular events in type 2 diabetes

Researchers find that a single questionnaire item assessing vitality predicts major adverse cardiovascular events in people with type 2 diabetes.

Nicola Milne

12-09-2022 | GLP-1 agonists | Ask the expert | Article

Initiating GLP-1 receptor agonists: Managing side effects

Specialist nurse Nicola Milne discusses the side effects that can arise in people with type 2 diabetes during initiation of GLP-1 receptor agonists, and how to best manage them.

09-09-2022 | COVID-19 | News

Microvascular complications linked to COVID-19 mortality risk in people with type 2 diabetes

Study findings suggest that the presence of microvascular complications is associated with increased risk for all-cause mortality in people with type 2 diabetes hospitalized for COVID-19.

02-09-2022 | Dapagliflozin | News

DELIVER results round-up: Frailty, AF, recent hospitalization, and more

A flurry of publications accompanying the primary findings of DELIVER shows dapagliflozin to benefit a wide range of people who have heart failure with preserved ejection fraction.

02-09-2022 | Diabetic foot | News

Most YouTube diabetic foot care videos ‘not adequate’

YouTube videos about diabetic foot examination are popular, but of poor quality, report UK researchers.

Doctor holds in his hands the kidney concept

01-09-2022 | Metformin | News

People with type 2 diabetes and CKD missing out on renoprotective drugs

People with type 2 diabetes and chronic kidney disease are substantially less likely to initiate SGLT2 inhibitors than those with normal kidney function, despite their proven renoprotective benefits, research shows.

Clinician holding a clear tablet with a heart image - cardiovascular research concept

31-08-2022 | Heart failure | News

‘Strikingly consistent’ evidence for SGLT2 inhibitor benefits across the spectrum of heart failure

SGLT2 inhibitors reduce the risk for adverse outcomes in a broad range of patients with heart failure, suggest findings from a meta-analysis of five randomized placebo-controlled trials.

27-08-2022 | Dapagliflozin | News

Dapagliflozin DELIVERs improved HFpEF outcomes

Dapagliflozin significantly reduces the risk for worsening heart failure or cardiovascular death in people who have heart failure with preserved ejection fraction, show the results of the DELIVER trial.

Close up of pain killer tablets and a woman in pain

25-08-2022 | Neuropathy | News

Common diabetic peripheral neuropathic pain treatments equivalent in OPTION-DM

Combination therapy with three commonly used medications has achieved similar levels of pain relief for people with diabetic peripheral neuropathic pain in the randomized OPTION-DM trial.

25-08-2022 | Physical activity | News

Initiating glucose-lowering therapy may be linked to a reduction in physical activity

Starting treatment with SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors is associated with a reduction in physical activity levels among some people with type 2 diabetes, researchers report.